The effects of niceritrol on serum lipids and apolipoproteins were investigated in 29 patients with hyperlipidemia for 12 weeks. Total cholesterol was decreased significantly by 5.4% after the treatment without lowering HDL cholesterol. The atherogenic index was decreased significantly. Serum triglyceride had a tendency to decrease but not significantly. In 13 patients with hypertrigly-ceridemia (more than 150mg/dl of triglyceride), serum triglyceride was decreased by 20%. The apolipoproteins A-I, A-II and B were decreased significantly. There were no effects on apolipoprotein C-II and C-III. Apolipoprotein E decreased significantly. Flushing occurred in 5 patients with hyperlipidemia, but other major side effects did not occure. These results suggested that niceritrol was effective in treatment of patients with hyperlipidemia.
